Skip to search formSkip to main contentSkip to account menu

NSC 352122

Known as: NSC-352122 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Trimetrexatetrimetrexate glucuronate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion
SummaryTrimetrexate (TMTX) is a potent inhibitor of dihydrofolate reductase that circumvents the transport resistance seen with… 
2004
2004
A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics
SummaryTrimetrexate glucuronate (TMTX), a non-classic folate antagonist, has been evaluated clinically on several schedules. We… 
1988
1988
Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
Trimetrexate (TMQ; NSC 352122) is a potent inhibitor of dihydrofolate reductase with good activity against murine i.p.-implanted… 
1987
1987
Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer.
The disposition of the methotrexate analogue trimetrexate (TMTX, NSC 352122; 2,4-diammino-5-methyl-6-[(3,4,5-trimethoxyanilino… 
1986
1986
Pharmacokinetics of trimetrexate (NSC 352122) in monkeys.
The pharmacokinetics of trimetrexate was studied in Rhesus monkeys following i.v. bolus, continuous i.v. infusion, oral, and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)